Home
Stampa
HomeStampa
HomeStampa
18:00 - 19:00 | Satellite Symposium
HIV and COVID-19: where we are and where we are going
19:00 - 20:30
ICAR 2023 Opening Session
20:30 - 22:30
ICAR 2023 Welcome Reception
15:00 - 17:30 | Pre-Conference advanced course
Current epidemiology and future perspectives on the prevention of STIs and HPV related anal cancer
15:00 - 17:30 | Special Session
RaccontART Contest Awards: incontro con le scuole finaliste e premiazione
15:00 - 17:30 | Pre-Conference advanced course
Clinical virology: dealing with HIV infection today
15:00 - 17:30 | Pre-Conference advanced course
HIV infection in the migrant and refugee population
Satellite Symposium
HIV and COVID-19: where we are and where we are going
Con la sponsorizzazione non condizionante di: 
Satellite Symposium
HIV and COVID-19: where we are and where we are going
The life expectancy of people living with HIV (PLHIV) is now close to the one of HIV negative individuals. This important milestone has been achieved thanks to the continuous evolution of antiretroviral therapy (ART), by providing new antiretroviral regimens providing high efficacy, genetic barrier, forgiveness, tolerability, and convenience. However, a 00virgolette00tailored00virgolette00 approach has to satisfy also needs and expectations of PLWH, in order to guarantee them a therapeutic success for long-term. The symposium is also aimed at providing new insights on SARS-CoV-2 infection, especially in high-risk populations, such as comorbid and immunocompromised individuals. Through an interactive talk, experts will discuss on challenges and current and future innovative strategies that can fill the unmet needs of people living with HIV and SARS-CoV-2, supporting individuals to overcome treatment barriers and improve their quality of life.
Chairs: G. Di Perri, C. Mussini
| Talk-show debate based on the following topics: | |
| 18.00 - 18.15 | What we need in HIV treatment today to achieve long term success?
S. Lo Caputo |
| 18.15 - 18.30 | What are the patients' needs in terms of adherence and forgiveness in HIV?
F. Maggiolo |
| 18.30 - 18.45 | COVID-19 and comorbidities. What challenges we need to face?
E. Nicastri |
| 18.45 - 19.00 | Discussion and final consideration |
ICAR 2023 Opening Session
ICAR 2023 Opening Session
Chairs: G.V. Calvino, F. Ceccherini Silberstein, A. d'Arminio Monforte, M. Formisano, G. Ippolito, S. Lo Caputo, A. Saracino, F. Schloesser
| 19.00 - 19.20 | Sigla ICAR 2023 |
| 19.00 - 19.20 | Introducing ICAR 2023. Chairs and Authorities' welcome addresses |
| RaccontART: the three Winners | |
| 19.20 - 20.20 | Keynote Lectures |
| 19.20 - 19.50 | Mauro Moroni Memorial Lecture: "Vaccine Hesitancy - A Story as Old as Vaccines Themselves"
C. Gainty |
| 19.50 - 20.20 | Video Ricordo di Giulio Maria Corbelli |
| 19.50 - 20.20 | Giulio Maria Corbelli Memorial Lecture: "Health pathways in transgender people. The denied rights of invisible people"
M. Formisano |
| 20.20 - 20.30 | Closing remarks |
ICAR 2023 Welcome Reception
ICAR 2023 Welcome Reception
Pre-Conference advanced course
Current epidemiology and future perspectives on the prevention of STIs and HPV related anal cancer
Pre-Conference advanced course
Current epidemiology and future perspectives on the prevention of STIs and HPV related anal cancer
Sexually Transmitted Infections (STIs) represent a concern for sexually active individuals. If undiagnosed, STIs can eventually cause serious complications. Immunization and pharmacological prophylaxis are emerging, as adjunct to periodic screening of asymptomatic people, as new strategies for approaching STIs in addition to treatment once the infection is established. A thorough overview of the current state of the art will be offered to participants. The dynamic of HPV transmission and the pathogenesis of this infection differs from the other STIs. The relevance of anal HPV infection and HPV related anal cancer among MSM and PLWH is emerging. The ANCHOR study represents a milestone in this field and its publication in June 2022 opened the way to the definition of the first screening guidelines for the prevention of this neoplasm, with particular attention to PLWH. A review of current literature on anal HPV infection and anal cancer risk among several key populations and a focus on these novel screening guidelines will be offered to participants.
Chairs: D. Calzavara, E.N. Cavallari
| 15.00 - 15.10 | Evaluation of participants' knowledge on the course topics through a live on-line questionnaire (APP)
D. Calzavara, E.N. Cavallari |
| 15.10 - 15.30 | New insights on vaccines to prevent STIs
D. Moschese |
| 15.30 - 15.50 | New insights on pharmacological approaches to prevent STIs
S. Venturelli |
| 15.50 - 16.15 | Discussion |
| 16.15 - 16.35 | HPV and anal cancer risk among MSM and PLWH
R.P. Iachetta |
| 16.35 - 16.55 | New screening guidelines for the prevention of HPV related anal cancer in MSM
M. Ridolfi |
| 16.55 - 17.20 | Discussion |
| 17.20 - 17.30 | Revaluation of participants' knowledge on the course topics through a live on-line questionnaire (APP)
D. Calzavara, E.N. Cavallari |
Special Session
RaccontART Contest Awards: incontro con le scuole finaliste e premiazione
Special Session
RaccontART Contest Awards: incontro con le scuole finaliste e premiazione
Giunto alla nona edizione e destinato agli studenti degli Istituti Scolastici Superiori, il Contest artistico RaccontART rappresenta un'occasione unica e preziosa di formazione e informazione in tema di HIV, Infezioni Sessualmente Trasmissibili e Covid-19. Questa sessione è dedicata alla presentazione delle Opere finaliste in concorso, selezionate dalle Giurie Artistica e Tecnico-Scientifica. Al termine della Sessione, verranno premiati i primi tre classificati.
Chairs: F. Ceccherini Silberstein, M. Formisano, S. Lo Caputo, A. Saracino
| 15.15 - 15.30 | Benvenuto e presentazione della Giuria Artistica e Tecnico-Scientifica
F. Ceccherini Silberstein, M. Errico |
| 15.30 - 17.00 | Presentazione delle Opere finaliste al Concorso a cura degli Istituti Scolastici
F. Ceccherini Silberstein, M. Errico |
| 17.00 - 17.15 | Premiazione primi 3 classificati |
| 17.15 - 17.30 | Conclusioni |
Pre-Conference advanced course
Clinical virology: dealing with HIV infection today
Pre-Conference advanced course
Clinical virology: dealing with HIV infection today
The scenario of HIV infection has dramatically changed in the last two decades. Since HIV became a treatable and "chronic disease", people living with HIV (PLHIV) require lifelong care and treatment. This is thanks to the progress of antiretroviral therapy (ART), which is increasingly effective, potent, tolerable and with a high genetic barrier. Concomitantly, the strategy for treating/preventing HIV infection has also changed over time: possibility of starting ART immediately upon diagnosis (test-and-treat), likely (virtually) increasing the chance of detect acute infection; opportunity to simplify the regimen in virosuppressed ART-experienced PLWH or prevent infection (pre-exposure prophylaxis, PrEP), using effective regimens with just two active components and/or based on long-acting injectable formulation. Both oral and injectable PREP have been shown to greatly reduce the risk (incidence) of HIV infection. In both ART-naive and -experienced PLWH, these strategies can promote retention in care, treatment adherence and drug tolerability, ultimately improving the overall quality of life of PLWH. Despite increasing evidence of the efficacy, safety and tolerability of these new strategies in both ART-naive and -experienced PLWH, it is mandatory to evaluate them in clinical practice settings. In this regard, it is crucial to strictly monitor and follow PLWH from the time of diagnosis, via: I) standard surrogate markers (CD4 and HIV-RNA); II) markers of inflammation/immune-activation panels; III) total HIV-DNA, as a marker of the reservoir; and IV) genotypic tests for detecting primary and secondary drug resistance. To date, microfluidic technologies (microfluidic ELISA, digital droplet PCR and "next generation sequencing), which have enhanced laboratory performances (higher sensitivity, higher throughput) could fulfil the needs of a routine practice in clinical virology improving, in turn, the management of "present-day" ART-naive and virologically suppressed PLWH.
Chairs: G. Lapadula, F. Lombardi
| 15.00 - 15.30 | Proviral DNA/transcription-competent reservoir as a marker for monitoring the efficacy of novel antiretroviral strategies (simplification/LA) in virosuppressed PLWH:
- clinical implication/interpretation of the results
F. Saladini |
| 15.30 - 16.00 | Diagnosis and Management of Acute HIV:
- Diagnostic algorithm
- Clinical relevance of early detection
V. Micheli |
| 16.00 - 16.30 | NGS in HIV: present and future challenges:
- Understand the cut-off for detection of the minority variants (clinical interpretation)
- Whole genome sequencing (WGS) in the light of new strategies based on antiretrovirals acting on several different targets
D. Armenia |
| 16.30 - 17.00 | A new paradigm for antiretroviral delivery: long-acting new antivirals and strategies for the treatment and prevention of HIV:
- Clinical and virological perspectives
R. Rossotti |
| 17.00 - 17.30 | Discussion |
Pre-Conference advanced course
HIV infection in the migrant and refugee population
Pre-Conference advanced course
HIV infection in the migrant and refugee population
There were around 281 million international migrants in the world in 2021, which equates to 3.6 per cent of the global population. Migrant populations are more likely to suffer from poor health in general and HIV infection in particular. This is due to the epidemiological burden in the country of origin, as well as the vulnerability conditions during travel and the poor living conditions once in Europe, which expose them to every vulnerability. In addition, as with other people living with HIV/AIDS, migrants who are HIV-positive are subject to stigmatization and discrimination, and therefore, they hide their HIV status as long as possible, thus making support services unavailable to them. Most migrant populations live in a legal vacuum, with no stay or work permit in the host country, making frequently this an element of non-access to health services. The aim of this course is to deepen our understanding of the migration phenomenon and HIV pathology by highlighting epidemiological data, good practises of public and private entities, sharing difficulties, and approaching the problem with possible, applicable, and sustainable solutions.
Chairs: A. Caraglia, M. Cascio, T.S. Prestileo
Discussants: F. Di Gennaro, L.A.R. Rancilio, C. Torti
| 15.00 - 15.20 | Migrant and refugees in Italy: current scenarios
D.P. Betti |
| 15.20 - 15.40 | HIV infection in migrant population - Learning from each other
C. Torti |
| 15.40 - 16.00 | NGOs as a first response for migrant integration and approach to the health system
L.A.R. Rancilio |
| 16.00 - 16.20 | Public health engagement of migrants: the role of Hospital and University
F. Di Gennaro |
| 16.20 - 17.30 | Round table |
09:00 - 10:00
Keynote Lectures
10:05 - 11:05 | Symposium
Controversies in HIV clinical virology
11:10 - 12:10 | Sponsored Symposium
HIV treatment outcomes with DTG/3TC in Naive and Experienced PLHIV
12:15 - 13:15 | Symposium
The case of weight gain: is it a relevant issue in the management of PWH? PROs and CONs
13:20 - 14:20 | Oral Communications
Clinical issues blinking to laboratory
14:30 - 15:30 | Sponsored Symposium
B/F/TAF: your trusted partner also in apparently un-complicated patients
15:35 - 16:35 | Symposium
New issues on antiretroviral drug optimization
16:40 - 18:00 | Symposium
How to manage Heavily Treatment-Experienced patients (HTE)
10:05 - 11:05 | Sponsored Symposium
Do mAbs still play a role in the early treatment of COVID-19 patients?
11:10 - 12:10 | Satellite Symposium
A new era of HDV treatment: relevance of HDV control in coinfected patients
12:15 - 13:15 | Oral Communications
Outcome in first-line regimens
13:20 - 14:20 | Oral Communications
Viral infections old and new
14:30 - 15:30 | Oral Communications
Antiviral treatment in COVID-19
15:35 - 16:35 | Satellite Symposium
From prevention to cure in SARS-CoV-2: bivalent vaccines and antiviral therapy
16:40 - 17:40 | Symposium
Immunotherapies in chronic viral infections: what will the future bring?
10:05 - 11:05 | Expert Meeting
Individualization and evolution of HIV management with the next generation of NNRTI: the future is now
11:10 - 12:10 | Oral Communications
Immune response in SARS-CoV-2
12:15 - 13:15 | Expert Meeting
Every left is lost, let's vaccinate
13:20 - 14:20 | Oral Communications
Preferences limitations and long term outcomes
14:30 - 15:30 | Expert Meeting
Long-acting antimicrobial experiences in real world patients: toward paradigm changement?
15:35 - 16:35 | Oral Communications
Severe clinical issues in HIV-1 infection
16:40 - 17:50 | Oral Communications
The increasing burden of STIs
10:05 - 11:05 | Oral Communications
Emerging immunological and virological concepts in viral hepatitis
11:10 - 12:10 | Oral Communications
Inflammation: a major pathogenetic process
12:15 - 13:15 | Oral Communications
One size does not fit all
13:20 - 14:20 | Oral Communications
Immune response to viruses
14:30 - 15:30 | Oral Communications
HIV: much left to do
15:35 - 16:35 | Oral Communications
Oral or injectable 2-drug regimens
16:40 - 17:50 | Oral Communications
Vaccine in frail patients
10:05 - 11:05 | Oral Communications
Epidemiology trends in infections
12:15 - 13:15 | Oral Communications
Early treatment for COVID-19
13:20 - 14:20 | Oral Communications
COVID-19 outcome in special population
14:30 - 15:30 | Oral Communications
Cardiovascular and malignancies
15:35 - 16:35 | Oral Communications
Prevention, access and engagement
16:40 - 17:40 | Oral Communications
Clinical outcome of SARS-CoV-2 infection
11:10 - 12:10 | Special Session
Health and prevention in transgender people
12:15 - 13:15 | Parallel Session
ARCA Scientific Board
15:35 - 16:35 | Special Session
The Italian Fast-track Cities: strengths and weaknesses of a growing movement
Keynote Lectures
Keynote Lectures
Chairs: G. Antonelli, F. Castelli, A. Gori
| 09.00 - 09.30 | All you always wanted to know about clinical pharmacology but were afraid to ask
S. Bonora |
| 09.30 - 10.00 | Simplifying a complex issue: how to tailor drug resistance into clinical practice
A.M. Geretti |
Symposium
Controversies in HIV clinical virology
Symposium
Controversies in HIV clinical virology
While modern antiretroviral therapy has been progressing towards increased potency, convenience and durability, controversies in HIV virology and pharmacology remain. This symposium focuses on two specific issues, namely HIV drug resistance and low-level viremia, through an attractive clinician vs. virologist format. The incidence of HIV drug resistance has been decreasing due to expanded use of high genetic barrier drugs and lower rates of virological failure. However, a proportion of PLWH still develop or harbour drug resistance patterns which can challenge treatment options. In addition, people with controlled viremia can benefit from HIV DNA drug resistance testing and the advent of high-resolution sequencing methods have recently added a new layer of opportunities and challenges. On the other hand, how to deal with low-level viremia remains an open debate requiring an integrated view on antiretroviral pharmacology, adherence and the risk of emergent resistance.
Chairs: A. Callegaro, A. Lazzarin
| 10.05 - 10.35 | Round Table: Should we still care about drug resistance?
The clinician's and virologist's view
V. Micheli |
| 10.05 - 10.35 | Round Table: Should we still care about drug resistance?
The clinician's and virologist's view
S. Rusconi |
| 10.35 - 11.05 | Round Table: How to deal with low-level viraemia.
Clinician and biologist in comparison
F. Lombardi |
| 10.35 - 11.05 | Round Table: How to deal with low-level viraemia.
Clinician and biologist in comparison
F. Maggiolo |
Sponsored Symposium
HIV treatment outcomes with DTG/3TC in Naive and Experienced PLHIV
Simposio promozionale di: 
Sponsored Symposium
HIV treatment outcomes with DTG/3TC in Naive and Experienced PLHIV
DTG/3TC has now demonstrated durable efficacy and tolerability both as a first-line regimen as well as in the setting of treatment optimization for experienced patients, at the same time reducing the number of antiretrovirals (compared to 3-4DR). In the setting of naïve patients, it is key to understand the criteria driving the treatment choice and the concerns associated with starting treatment with a 2DR such as DTG/3TC to compare them with the evidences available both from RCTs and real-world experiences. On the other hand, proactive treatment optimization and simplification in the experienced patient is becoming much more relevant as we focus on a preventive approach to improve the quality of life in the context of a lifelong therapy. Therefore, the aim of this symposium is discussing the most recent evidences available that supports the use of DTG/3TC in these settings.
Chairs: S. Rusconi, M. Santoro
| 11.10 - 11.20 | Opening: relevance of long term perspectives in current HIV care
S. Rusconi, M. Santoro |
| Round table | |
| 11.20 - 11.35 | Decision criteria and concerns around DTG/3TC usage in naive patients
N. Gianotti |
| 11.35 - 11.50 | Long-term outcomes of treatment simplification:
the role of DTG/3TC
S. Di Giambenedetto |
| 11.50 - 12.05 | DTG/3TC and metabolic health
N. Squillace |
| 12.05 - 12.10 | Closing and take home messages
S. Rusconi, M. Santoro |
Symposium
The case of weight gain: is it a relevant issue in the management of PWH? PROs and CONs
Symposium
The case of weight gain: is it a relevant issue in the management of PWH? PROs and CONs
Weight gain in people on antiretroviral treatment has been observed in numerous cohorts and continues to be an issue of intense debate. Indeed, several aspects are not yet clear: how weight gain is affected by specific antiretroviral treatments, pre-existing body weight or other factors, what are the underlying mechanisms, and to what extent is this a clinically relevant issue, depending on actual rate and extent and associations with metabolic disorders and other conditions. This symposium aims to weight pros and cons from ID and other specialists on whether weight gain is clinically relevant in PWH and gain knowledge towards optimal management.
Chairs: P. Bonfanti, F. Vichi
| 12.15 - 12.20 | Introduction
G. Madeddu |
| 12.20 - 12.30 | YES, weight gain is a truly relevant issue
P. Maggi |
| 12.30 - 12.40 | NO, weight gain is not that much relevant afterall
S. Cicalini |
| 12.40 - 12.50 | The association of weight gain with (diabetes and) metabolic alterations: an endocrinological view
D. Gianfrilli |
| 12.50 - 13.00 | Increased CV risk related to minimal to substantial weight gain: a cardiovascolar view
G. d'Ettorre |
| 13.00 - 13.15 | Round Table and conclusion
P.M. Cinque, F. Vichi |
Oral Communications
Clinical issues blinking to laboratory
Oral Communications
Clinical issues blinking to laboratory
Chairs: S. Cicalini, C. Gervasoni
| 13.20 - 13.25 | Introduction
S. Cicalini, C. Gervasoni |
| 13.25 - 13.35 | OC 29 Weight gain and loss and stable weight in relation to fat and lean mass in PWH
|
| 13.37 - 13.47 | OC 30 Predicting Major Cardiovascular Events in People Living with HIV: a Prospective Observational Study
|
| 13.49 - 13.59 | OC 31 Long-term CD4+ cells recovery in PLWH on active antiretroviral treatment
|
| 14.01 - 14.11 | OC 32 A comprehensive analysis of total and integrated HIV DNA, CD4 and CD8 T cell response, and survival, quiescence, and stemness signaling at different stages of HIV infection
|
| 14.13 - 14.20 | Conclusion
S. Cicalini, C. Gervasoni |
Sponsored Symposium
B/F/TAF: your trusted partner also in apparently un-complicated patients
Simposio promozionale di:
Sponsored Symposium
B/F/TAF: your trusted partner also in apparently un-complicated patients
Gilead, a historical company involved in advancing HIV therapy, will host a promotional symposium called "B/F/TAF: Your trusted partner also in apparently uncomplicated patients." The symposium will focus on apparently uncomplicated patients in order to better understand their characteristics and raise awareness of the complexity of HIV. Through an analysis of patients' clinical needs, the often-overlooked CNS adverse events, the importance of long-term safety in therapy, and the need to control viral replication for as long as possible, we will draw on the experience of B/F/TAF to present key data on long-term safety and maximal and durable viral suppression, with the aim of identifying the optimal treatment choices for these patients.
Chair: G.C. Marchetti
| 14.30 - 14.35 | Introduction
G.C. Marchetti |
| 14.35 - 14.45 | Gilead's commitment in HIV
F. da Silva |
| 14.30 - 14.35 | Apparently un-complicated PLWH
G.C. Marchetti |
| 14.45 - 15.05 | Maximal and durable viral suppression in apparently un-complicated HIV Patients: The role of B/F/TAF
S. Bonora |
| 15.05 - 15.25 | The confidence of B/F/TAF Long-Term Safety in HIV Treatment
G. Madeddu |
| 15.25 - 15.30 | Q&A
G.C. Marchetti |
Symposium
New issues on antiretroviral drug optimization
Symposium
New issues on antiretroviral drug optimization
With currently available antiretroviral therapy, most people with HIV infection can achieve and maintain HIV viral suppression. Advances in antiretroviral treatment and a better understanding of drug resistance have made it possible to consider switching a person with HIV from an effective regimen to another in defined circumstances. New burning topics including the significance of the archived and resistant HIV, will be discussed
Chairs: S. Di Giambenedetto, G. Rizzardini
| 15.35 - 15.50 | Role and impact of drug-resistant and archived HIV
M. Zazzi |
| 15.50 - 16.05 | How much adherence is necessary to avoid drug-resistance with modern ART 2DRs and 3DRs?
A. Di Biagio |
| 16.05 - 16.20 | Pharmacological interactions: ART and the rest of world
A. Calcagno |
| 16.20 - 16.35 | Discussion |
Symposium
How to manage Heavily Treatment-Experienced patients (HTE)
Con la sponsorizzazione non condizionante di:
Symposium
How to manage Heavily Treatment-Experienced patients (HTE)
HTE patients are described as those having two or less antiretroviral (ARV) classes available for use with limited fully active ARV agents within each class. A detailed understanding of the underlying processes that caused previous treatment failures, diagnostics to define resistance, resistance mechanisms and ARV pharmacology should all function in tandem to determine the next steps of clinical care. This Symposium provides an overview of the clinical approach to care, including diagnostics, regimen creation and a broad array of both currently available and upcoming ARVs that may be used in regimens for HTE patients.
Chairs: M. Galli, F. Maggiolo, M. Santoro
Moderators: F. Maggiolo, M. Santoro
Discussants: A. Castagna, A. Di Biagio, S. Lo Caputo, S. Rusconi
| 16.40 - 16.55 | Who are the HTE patients?
S. Lo Caputo |
| New classes of antiretroviral drugs with novel mechanisms of action: | |
| 16.55 - 17.10 | Fostemsavir, the HIV-1 attachment inhibitor
S. Rusconi |
| 17.10 - 17.25 | Lenacapavir, the inhibitor of HIV capsid function
A. Di Biagio |
| 17.25 - 17.40 | U=U in HTE patients: myth or reality?
A. Castagna |
| 17.40 - 18.00 | Q&A and Panel Discussion |
Sponsored Symposium
Do mAbs still play a role in the early treatment of COVID-19 patients?
Simposio promozionale di: 
Sponsored Symposium
Do mAbs still play a role in the early treatment of COVID-19 patients?
Even if the epidemiology of COVID-19 has a significant decline there is still a significant unmet need related to the management of fragile patients with COVID-19 that despite vaccination can not build an immune response that can stop SARS-CoV2 reducing hospitalization or death progression in particular in the Early Treatment setting. Actually, in Italy the weekly mortality rate of patients with COVID-19 is still high ranging from 200 to 250 patients. The evolution of the VOCs resulting in the actual omicron soup has increased COVID-19 immune escape to mAbs generally, dramatically reducing in vitro neutralizing efficacy of the majority of mAbs and only sotrovimab maintain a moderate fold reduction in vitro and vivo that can be compensated di pharmacodynamic (effector functions) and pharmacokinetic properties such as blood concentration and pulmonary system persistency. In addition, recent studies have shown that people who are immunocompromised may inadvertently play a role in spurring the mutations of the virus that create new variants. This is because some immunocompromised individuals remain at risk of getting COVID-19 despite vaccination, experience more severe disease, are susceptible to being chronically infected and remain contagious for longer if they become infected and considering that immunocompromised individuals represent approximately 2% of the overall population, this aspect should be carefully considered. So the question is the title of this Symposia Do mAbs still play a role in the ET of COVID-19 patients? and the answer is yes and in particular sotrovimab going beyond in vitro data that with an evidence and experience based approach has the most robust Real World Evidences even in the most difficult to treat patient by fulfilling the unmet clinical needs of the three fragile patients' dimensions: aging, impact of comorbid condition and immunocompromised patients illness or treatment related. The talk show format and the shoot the piano player final session are going to animate discussion with experts and attendees.
Chairs: C.F. Perno, A. Saracino
| 10.05 - 10.20 | Rational criteria for evaluating mAbs efficacy: beyond in vitro data
C.F. Perno |
| Talk Show: Tailored experience-based approach on at risk COVID-19 patient dimensions: | |
| 10.20 - 10.30 | Aging
o Why can aging influence immune response of COVID-19 patients?
o How aging is correlated with COVID-19 mortality?
o Which criteria should we use to select mAbs or AVs in this type of patients based on your clinical experience?
G. Madeddu |
| 10.30 - 10.40 | Frailty
o Which chronic comorbidities are more associated with higher risk of COVID-19 patients' progression?
o How multimorbidities and related treatments can worsen clinical outcomes of COVID-19 patients?
o Which criteria should we use to select mAbs or AVs in this type of patients based on your clinical experience?
A.M. Cattelan |
| 10.40 - 10.50 | Vulnerability
o Why immunocompromised patients are more associated with higher risk of COVID-19 patients' progression?
o Which pharmacological and surgical immunosuppressive treatments can worsen clinical outcomes of COVID-19 patients? (positivity, viral load, symptoms)
o Which criteria should we use to select mAbs or AVs in this type of patients based on your clinical experience?
V. Mazzotta |
| 10.50 - 11.05 | Shoot the Piano Player Experts Q&A session
A. Saracino |
Satellite Symposium
A new era of HDV treatment: relevance of HDV control in coinfected patients
Con la sponsorizzazione non condizionante di:
Satellite Symposium
A new era of HDV treatment: relevance of HDV control in coinfected patients
Hepatitis delta virus (HDV) is a defective agent that only infects individuals with hepatitis B virus (HBV). Around 5-10% of chronic hepatitis B patients worldwide are superinfected with HDV, which means 15-25 million people. Hepatitis delta is the most severe of all chronic viral hepatitis, leading to cirrhosis, liver cancer and/or transplantation in most patients. The only treatment available until recently was peginterferon alfa, with poor results and significant side effects. The recent approval of bulevirtide, a lipopeptide that blocks HBV/HDV entry, has revolutionized the field. Given that sexual and parenteral transmission routes are the most frequent for the acquisition of HBV and HDV, shared with HIV infection and HBV/HDV and HIV coinfection. The clinical outcome of hepatitis delta is worst in the HIV setting, with more frequent liver complications.
Chairs: A. d'Arminio Monforte, T.A. Santantonio
| 11.10 - 11.30 | New therapeutic options for HDV: from RCT to Real world
E. Degasperi |
| 11.30 - 11.50 | HIV-HBV-HDV coinfected patients in ICONA Cohort: practical management recommendations
M. Puoti |
| 11.50 - 12.00 | Discussion |
| 12.00 - 12.10 | The patient voice
C. Taibi |
Oral Communications
Outcome in first-line regimens
Oral Communications
Outcome in first-line regimens
Chairs: S.M. Ferrara, N. Gianotti
| 12.15 - 12.20 | Introduction
S.M. Ferrara, N. Gianotti |
| 12.20 - 12.30 | OC 17 Effectiveness of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in real-world setting in ART-naive patients: data from the Icona cohort
|
| 12.32 - 12.42 | OC 18 Effectiveness of first-line lamivudine-dolutegravir (3TC-DTG) antiretroviral therapy (ART) in persons living with HIV (PLWH): real-life data from the ICONA Foundation cohort
|
| 12.44 - 12.54 | OC 19 Body weight and plasma lipids changes in person living with HIV (PLWH) starting double or triple INSTI-based cART regimens
|
| 12.56 - 13.06 | OC 20 HIV-DNA decay in ART-naïve PLWH starting dolutegravir plus lamivudine vs triple therapy: 48-week results in a real-life setting
|
| 13.08 - 13.15 | Conclusion
S.M. Ferrara, N. Gianotti |
Oral Communications
Viral infections old and new
Oral Communications
Viral infections old and new
Chairs: V. Micheli, L. Sarmati
| 13.20 - 13.25 | Introduction
V. Micheli, L. Sarmati |
| 13.25 - 13.35 | OC 33 APRI and FIB-4 scores predict mortality and morbidity in HCV infected subjects after sustained virologic response over the long-term
|
| 13.37 - 13.47 | OC 34 Common seasonal respiratory viral infections during nine consecutive seasons (2014-2023), including Coronavirus disease (COVID-19) pandemic
|
| 13.49 - 13.59 | OC 35 Seroprevalence of Monkeypox (MPX) IgG antibodies in a cohort of PLWH in Rome, during the 2022 outbreak
|
| 14.01 - 14.11 | OC 36 Case series of Monkeypox in a sexual health clinic in Milan
|
| 14.13 - 14.20 | Conclusion
V. Micheli, L. Sarmati |
Oral Communications
Antiviral treatment in COVID-19
Oral Communications
Antiviral treatment in COVID-19
Chairs: A. Franco, M. Lichtner
| 14.30 - 14.35 | Introduction
A. Franco, M. Lichtner |
| 14.35 - 14.45 | OC 49 Prolonged antiviral therapy combined with neutralizing monoclonal antibodies as a treatment strategy for COVID-19 in severely immunocompromised patients during the Omicron wave: a quasi-experimental multicentre cohort study
|
| 14.47 - 14.57 | OC 50 Anti-spike monoclonal antibodies to prevent hospitalization in mild COVID-19: final analysis of an observational multicenter study (CONDIVIDIAMO)
|
| 14.59 - 15.09 | OC 51 Clinical efficacy of tixagevimab/cilgavimab pre-exposure prophylaxis in immunocompromised patients treated during Omicron sublineages diffusion. Real life experience from ASST Lecco
|
| 15.11 - 15.21 | OC 52 Vaccination and antiviral treatment reduce the time to negative SARS-CoV-2 swab: a real-life study
|
| 15.23 - 15.30 | Conclusion
A. Franco, M. Lichtner |
Satellite Symposium
From prevention to cure in SARS-CoV-2: bivalent vaccines and antiviral therapy
Con la sponsorizzazione non condizionante di:
Satellite Symposium
From prevention to cure in SARS-CoV-2: bivalent vaccines and antiviral therapy
COVID-19 places tremendous burden to public health and economy system. The roll-out of COVID-19 vaccines at the beginning of 2021 marked a key turning point in the fight against the global pandemic by limiting disease transmission and progression to death, albeit variable vaccination coverage. Early antiviral treatments can help reduce the risk of serious illness especially in adults at high risk of progressing to severe COVID-19 (as immunocompromised individuals) and may continue to shed virus and remain symptomatic for a longer period.
Chairs: A. Cingolani, R. Parrella
| 15.35 - 15.50 | SARS-CoV-2 early antiviral treatment: in which patients?
M. Andreoni |
| 15.50 - 16.05 | Antiviral therapy in COVID-19 patients
A. Antinori |
| 16.05 - 16.15 | Discussion |
| 16.15 - 16.30 | SARS-CoV-2 bivalent vaccines efficacy in today's epidemiological scenario
P.L. Lopalco |
| 16.30 - 16.35 | Discussion |
Symposium
Immunotherapies in chronic viral infections: what will the future bring?
Symposium
Immunotherapies in chronic viral infections: what will the future bring?
Immunotherapies, already well established in the management of cancer, are emerging as important tools in the control of chronic viral infections. There are challenges: we need to understand whether stimulating a sluggish immune response, tackling immune inhibition, or directly transferring immune mediators is the best approach; we must carefully consider potential safety liabilities; and we wish for improved biomarkers to optimise patient stratification and monitoring. We will discuss two different scenarios that pose different risk/benefit considerations but are equally challenging. Firstly, we will talk about the initial hopes, subsequent disappointments and current promising approaches that bring us closer to curing chronic HBV infection. A brief case history will then highlight the problem of CMV infection unresponsive to traditional interventions in the setting of immunodeficiency, followed by a lecture on how transfer of CMV-specific T-cells can restore protective antiviral immunity in transplant recipients patients. Come along to this exciting symposium to hear how cutting-edge science is being translated into clinical practice!
Chairs: N. Coppola, V. Svicher
Discussants: P.E. Comoli, N. Coppola, P. Fisicaro, A.M. Geretti, M. Lichtner, V. Svicher
| 16.40 - 17.00 | Immunotherapies to cure chronic HBV infection
P. Fisicaro |
| 17.00 - 17.05 | Case history: The challenge of unresponsive CMV infection
M. Lichtner |
| 17.05 - 17.25 | Adoptive immunotherapies for CMV and other viruses in the transplant setting
P.E. Comoli |
| 17.25 - 17.40 | Q&A and Panel Discussion |
Expert Meeting
Individualization and evolution of HIV management with the next generation of NNRTI: the future is now
Con la sponsorizzazione non condizionante di:
Expert Meeting
Individualization and evolution of HIV management with the next generation of NNRTI: the future is now
One size doesn't fit all. Prevention and management of comorbidities. How does it impact your practice? Interactive discussion on cardio-metabolic disorders, DDI and polypharmacy and resistance to support PLWH with the first of the new generation of NNRTI.
Chair: A. Castagna
Discussants: B.M. Celesia, R. Gagliardini, C. Gervasoni, P. Maggi
| The unmet medical needs for people living with HIV infection
B.M. Celesia |
|
| Individualization and evolution of HIV management with the next generation of NNRTI: the future is now - Doravirine: efficacy and resistance data in trial and in real life
R. Gagliardini |
|
| La gestione del rischio CV
P. Maggi |
|
| Individualization and evolution of HIV management with the next generation of NNRTI: the future is now
C. Gervasoni |
Oral Communications
Immune response in SARS-CoV-2
Oral Communications
Immune response in SARS-CoV-2
Chairs: M. Biasin, C. Tincati
| 11.10 - 11.15 | Introduction
M. Biasin, C. Tincati |
| 11.15 - 11.25 | OC 9 Monocytes and NK cell subsets frequencies after anti-S monoclonal antibodies treatment in COVID-19 patients
|
| 11.27 - 11.37 | OC 10 ERAPs control In Vitro SARS-CoV-2 Infection by triggering NK and Neutrophil activation
|
| 11.39 - 11.49 | OC 11 A novel enhancing effect of SARS-CoV-2 mutations on anti-viral CD8 T cell responses
|
| 11.51 - 12.01 | OC 12 Neutralizing antibodies response to novel SARS-CoV-2 omicron sublineages in long-term care facility residents after the fourth dose of monovalent BNT162b2 COVID-19 vaccination
|
| 12.03 - 12.10 | Conclusion
M. Biasin, C. Tincati |
Expert Meeting
Every left is lost, let's vaccinate
Expert Meeting
Every left is lost, let's vaccinate
Some infectious diseases are preventable, and vaccination is one of the most effective and safe measure in Public Health for their primary prevention. Over time, the introduction of vaccinations has made it possible to reduce the spread of some serious and deadly diseases, or even to eliminate them. Although, paradoxically, it is precisely the success of vaccinations that creates problems in their acceptance, since the decrease in the frequency of these preventable diseases has led to a decrease in the perception of their severity. The immunocompromised patient is among the ones at greater risk of infections, and therefore vaccinations become fundamental for its management. Among vaccinations recommended for immunocompromised patients the main are against: flu, herpes zoster, pneumococcus and meningococcus. In this process, the infectious disease specialist has a central role for both the patient and the other specialists involved.
Chairs: C.M. Mastroianni, O. Turriziani
Discussants: M. Andreoni, M. Conversano, I. Gentile
| Every left is lost, let’s vaccinate
M. Andreoni |
|
| Herpes Zoster: dal quadro sindromico alla prevenzione
I. Gentile |
Oral Communications
Preferences limitations and long term outcomes
Oral Communications
Preferences limitations and long term outcomes
Chairs: A. Cascio, E. Girardi
| 13.20 - 13.25 | Introduction
A. Cascio, E. Girardi |
| 13.25 - 13.35 | OC 37 Real world data on PROs and pharmacokinetics in PLWH starting long-acting injectable antiretroviral therapy (LAI-ART)
|
| 13.37 - 13.47 | OC 38 Perceived health discrimination and normative stigma: health consequences in a cohort of People living with HIV
|
| 13.49 - 13.59 | OC 39 Outcome of tenofovir and integrase inhibitors-including ART in PLWH and HBV: data from the SCOLTA cohort
|
| 14.01 - 14.11 | OC 40 Missing data generate missing opportunities: frailty phenotype assessment in the GEPPO cohort
|
| 14.13 - 14.20 | Conclusion
A. Cascio, E. Girardi |
Expert Meeting
Long-acting antimicrobial experiences in real world patients: toward paradigm changement?
Expert Meeting
Long-acting antimicrobial experiences in real world patients: toward paradigm changement?
The long-acting lipoglycopeptides (LGPs) are antimicrobials with broad and potent activity against Gram-positive bacterial pathogens. While they are approved for acute bacterial skin and soft tissue infections (ABSSSI), their pharmacological properties suggest a potential role of these agents for the treatment of deep-seated and severe infections, such as diabetic foot, bone and joint infections. The use of these antimicrobials is particularly appealing when prolonged therapy, early discharge, and multidrug-resistant bacteria are suspected.
Chairs: S. Carbonara, A.M. Cattelan
| 14.30 - 14.45 | In the diabetic patient
G. Di Perri |
| 14.45 - 15.00 | In bacterial coinfection
G. Parruti |
| 15.00 - 15.15 | Clinical practice and pharmacoeconomic aspects
S. Carbonara |
| 15.15 - 15.30 | Discussion |
Oral Communications
Severe clinical issues in HIV-1 infection
Oral Communications
Severe clinical issues in HIV-1 infection
Chairs: A. Cozzi-Lepri, M. De Gennaro
| 15.35 - 15.40 | Introduction
A. Cozzi-Lepri, M. De Gennaro |
| 15.40 - 15.50 | OC 61 Lower AIDS-related hospitalizations in women living with HIV multidrug resistance: results from the PRESTIGIO registry
|
| 15.52 - 16.02 | OC 62 Malignancies in PLWH: a 20-year experience in Perugia and Ancona hospitals
|
| 16.04 - 16.14 | OC 63 Clinical presentation and neuroimaging in newly diagnosed AIDS patients in the last 6 years
|
| 16.16 - 16.26 | OC 64 Prolonged survival in HIV-associated progressive multifocal leukoencephalopathy (PML) treated with Pembrolizumab: a case series on treatment and long-term follow-up
|
| 16.28 - 16.35 | Conclusion
A. Cozzi-Lepri, M. De Gennaro |
Oral Communications
The increasing burden of STIs
Oral Communications
The increasing burden of STIs
Chairs: S. Cecere, B. Suligoi
| 16.40 - 16.45 | Introduction
S. Cecere, B. Suligoi |
| 16.45 - 16.55 | OC 73 A cross sectional study of sexually transmitted infections in a northern Italy STI clinic
|
| 16.57 - 17.07 | OC 74 Sexually Transmitted Infections In Men With Multidrug-Resistant Human Immunodeficiency Virus: Data From The PRESTIGIO Registry
|
| 17.09 - 17.19 | OC 75 Temporal trends in incidence of bacterial sexually transmitted infections among PrEP users of Milano Checkpoint
|
| 17.21 - 17.31 | OC 76 Trends of Antimicrobial Susceptibility of Neisseria gonorrhoeae isolates between 2012 and 2023: a single-center experience in Milan, Italy
|
| 17.33 - 17.43 | OC 77 Predictors of mpox duration and severity in an Italian multicenter cohort (Mpox-ICONA)
|
| 17.45 - 17.50 | Conclusion
S. Cecere, B. Suligoi |
Oral Communications
Emerging immunological and virological concepts in viral hepatitis
Oral Communications
Emerging immunological and virological concepts in viral hepatitis
Chairs: N. Coppola, V. Svicher
| 10.05 - 10.10 | Introduction
N. Coppola, V. Svicher |
| 10.10 - 10.20 | OC 1 Ultrasensitive HBV-RNA quantification as a promising biomarker to optimize the staging of chronic HBV infection and to detect minimal viral activity under prolonged virological suppression and occult HBV infection
|
| 10.22 - 10.32 | OC 2 Functional and transcriptional restoration of exhausted virus-specific T lymphocytes from patients with chronic hepatitis B
|
| 10.34 - 10.44 | OC 3 HDV viral decline in HIV-infected and uninfected subjects with HBV/HDV-related cirrhosis during “real world” bulevirtide compassionate use program at INMI Spallanzani in Rome, Italy
|
| 10.46 - 10.56 | OC 4 Successful treatment of resistant HCV in ten patients, failed for other DAA, with glecaprevir/pibrentasvir and sofosbuvir
|
| 10.58 - 11.05 | Conclusion
N. Coppola, V. Svicher |
Oral Communications
Inflammation: a major pathogenetic process
Oral Communications
Inflammation: a major pathogenetic process
Chairs: A. De Maria, D.L. Trabattoni
| 11.10 - 11.15 | Introduction
A. De Maria, D. Trabattoni |
| 11.15 - 11.25 | OC 13 Effects of cART on residual inflammation and HIV reservoirs in Primary and Chronic HIV infection
|
| 11.27 - 11.37 | OC 14 Switching to doravirine reduces chronic inflammation among virologically controlled PLWH: 48 weeks results from the DORAGE cohort
|
| 11.39 - 11.49 | OC 15 Antiretroviral therapy partially restores phenotypic and metabolic immunosenescence features of T cells in HIV infected individuals
|
| 11.51 - 12.01 | OC 16 Human endogenous retroviruses expression correlates with HIV reservoir, lymphocytes activation and low CD4 count in virologically suppressed patients
|
| 12.03 - 12.10 | Conclusion
A. De Maria, D. Trabattoni |
Oral Communications
One size does not fit all
Oral Communications
One size does not fit all
Chairs: S. Babudieri, I. Pennini
| 12.15 - 12.20 | Introduction
S. Babudieri, I. Pennini |
| 12.20 - 12.30 | OC 21 Sexual and reproductive unmet clinical needs in Italian women living with HIV: results from Marilyn study
|
| 12.32 - 12.42 | OC 22 COVID perceptions among pregnant women living in a malaria hyperendemic rural region in Uganda: a cross-sectional study
|
| 12.44 - 12.54 | OC 23 Life quality and psychological health of women living with HIV: insight from a single centre in Sassari, Italy
|
| 12.56 - 13.06 | OC 24 HIV in prison setting: what about inmates? The four-years experience including SARS-CoV2 pandemic period in Florence
|
| 13.08 - 13.15 | Conclusion
S. Babudieri, I. Pennini |
Oral Communications
Immune response to viruses
Oral Communications
Immune response to viruses
Chairs: C. Agrati, I. Vicenti
| 13.20 - 13.25 | Introduction
C. Agrati, I. Vicenti |
| 13.25 - 13.35 | OC 41 Humoral and cell-mediated immunity against SARS-CoV-2 in dialysis patients after the vaccination with mRNA-1273 and BNT162b2 vaccines
|
| 13.37 - 13.47 | OC 42 Immune response triggered by a candidate vaccine based on a clone of Leishmania tarentolae expressing the SARS-CoV-2 Spike protein
|
| 13.49 - 13.59 | OC 43 Specific T-cell responses to Varicella Zoster Virus glycoprotein E are elicited after vaccination with a recombinant adjuvanted subunit vaccine in patients with multiple sclerosis on immune modulating treatments
|
| 14.01 - 14.11 | OC 44 Interferon and inflammatory response in SARS-CoV-2 infected patients treated with anti-S monoclonal antibodies
|
| 14.13 - 14.20 | Conclusion
C. Agrati, I. Vicenti |
Oral Communications
HIV: much left to do
Oral Communications
HIV: much left to do
Chairs: M. Farinella, S. Mattioli
| 14.30 - 14.35 | Introduction
M. Farinella, S. Mattioli |
| 14.35 - 14.45 | OC 53 HIV and hospitals: an evolving relationship
|
| 14.47 - 14.57 | OC 54 Achieving the third 95 in our HIV clinics: it is possible, but there is still a lot to do
|
| 14.59 - 15.09 | OC 55 Implementation of the Regional DCA 401/2016 in Latium: an example of a coordinated, multidisciplinary and individualized approach to PLWH territorial healthcare, forerunner of the National Recovery and Resilience Plan (PNRR) indications
|
| 15.11 - 15.21 | OC 56 BELONG – Why people living with HIV must be included in non-HIV Clinical Trials. A community-led initiative for an inclusive approach to clinical research
|
| 15.23 - 15.30 | Conclusion
M. Farinella, S. Mattioli |
Oral Communications
Oral or injectable 2-drug regimens
Oral Communications
Oral or injectable 2-drug regimens
Chairs: V. Esposito, A. Tavelli
| 15.35 - 15.40 | Introduction
V. Esposito, A. Tavelli |
| 15.40 - 15.50 | OC 65 “With age comes wisdom”: efficacy and tolerability of dolutegravir+lamivudine in virologically-suppressed PLWH
|
| 15.52 - 16.02 | OC 66 Assessing long-term risk of virological failure in PLWHIV starting dolutegravir+lamivudine as a switch strategy
|
| 16.04 - 16.14 | OC 67 Characteristics and clinical features of patients receiving LA CAB/RPV in a large clinical centre
|
| 16.16 - 16.26 | OC 68 3-month outcome of long-acting cabotegravir and rilpivirine: preliminary results from the SCohoLART Study
|
| 16.28 - 16.35 | Conclusion
V. Esposito, A. Tavelli |
Oral Communications
Vaccine in frail patients
Oral Communications
Vaccine in frail patients
Chairs: S. Antinori, S. Nozza
| 16.40 - 16.45 | Introduction
S. Antinori, S. Nozza |
| 16.45 - 16.55 | OC 78 Pneumococcal vaccination coverage among people living with HIV before and after the implementation of an on-site vaccination service at an HIV clinic: a retrospective observational study
|
| 16.57 - 17.07 | OC 79 SARS-CoV-2 mRNA vaccination and viro-immunological changes in PLWH
|
| 17.09 - 17.19 | OC 80 Specific humoral and T-cell response to three doses of SARS-CoV-2 mRNA vaccine in solid organ transplant recipients
|
| 17.21 - 17.31 | OC 81 Humoral and cell-mediated immune responses in elderly residing in a retirement house after 4 doses of anti-SARS-CoV-2 BNT162b2 vaccine
|
| 17.33 - 17.43 | OC 82 Assessment of SARS-CoV-2 specific T-cell responses using an in-house interferon-g release assay (IGRA) in people with HIV
|
| 17.45 - 17.50 | Conclusion
S. Antinori, S. Nozza |
Oral Communications
Epidemiology trends in infections
Oral Communications
Epidemiology trends in infections
Chairs: E. Girardi, B. Marchini
| 10.05 - 10.10 | Introduction
E. Girardi, B. Marchini |
| 10.10 - 10.20 | OC 5 HIV-1 Transmitted Drug Resistance in Newly Diagnosed Individuals in Italy Over the Period 2015-2021
|
| 10.22 - 10.32 | OC 6 Genomic epidemiology of the main SARS-CoV-2 variants circulating in Italy in 2020 and 2021 period
|
| 10.34 - 10.44 | OC 7 Trends of testing for HIV and syphilis in community based voluntary counselling and testing (CBVCT) services in the period 2019-2022: are there people more at risk?
|
| 10.46 - 10.56 | OC 8 Epidemiological and perceived health status determinants of early access to vaccine in Latium region Mpox vaccination (MpoxV) campaign
|
| 10.58 - 11.05 | Conclusion
E. Girardi, B. Marchini |
Oral Communications
Early treatment for COVID-19
Oral Communications
Early treatment for COVID-19
Chairs: E. Nicastri, M. Tavio
| 12.15 - 12.20 | Introduction
E. Nicastri, M. Tavio |
| 12.20 - 12.30 | OC 25 Incidence and predictors of clinical progression in an early treated COVID-19 multicentric cohort of an Italian Region
|
| 12.32 - 12.42 | OC 26 Impact of active and passive SARS-CoV-2 immunization on CAR-T patients: an Italian experience
|
| 12.44 - 12.54 | OC 27 Oral Antivirals against SARS-CoV-2: a Comparison between Molnupiravir and Nirmatrelvir/Ritonavir in a Real Life Setting
|
| 12.56 - 13.06 | OC 28 Efficacy, tolerability and prescribing choice in patients undergoing early therapy for COVID19: a single-center 2-years real life experience
|
| 13.08 - 13.15 | Conclusion
E. Nicastri, M. Tavio |
Oral Communications
COVID-19 outcome in special population
Oral Communications
COVID-19 outcome in special population
Chairs: G.B. Buccoliero, R. Rossotti
| 13.20 - 13.25 | Introduction
G.B. Buccoliero, R. Rossotti |
| 13.25 - 13.35 | OC 45 Efficacy of Tixagevimab/Cilgavimab pre-exposure prophylaxis of COVID-19 in severely immunocompromised individuals: data from the OCTOPUS study
|
| 13.37 - 13.47 | OC 46 Outcomes and clinical features of COVID‐19 patients with haematological malignancies in the Omicron era
|
| 13.49 - 13.59 | OC 47 COVID-19 in PLWH: clinical outcomes, a single center analysis
|
| 14.01 - 14.11 | OC 48 Molecular characterization of SARS-CoV-2 Omicron clade and clinical presentation in children
|
| 14.13 - 14.20 | Conclusion
G.B. Buccoliero, R. Rossotti |
Oral Communications
Cardiovascular and malignancies
Oral Communications
Cardiovascular and malignancies
Chairs: F. Mazzotta, M.E. Quiros Roldan
| 14.30 - 14.35 | Introduction
F. Mazzotta, M.E. Quiros Roldan |
| 14.35 - 14.45 | OC 57 Malignancies and MACEs in the PRESTIGIO Registry
|
| 14.47 - 14.57 | OC 58 Cardiovascular events on integrase strand-transfer inhibitors treatment
|
| 14.59 - 15.09 | OC 59 Multidimensional evaluation of switching from a first generation 3 drug (DR) INSTI regimen to a second generation 3DR- or 2DR INSTI regimen: a single Center retrospective Desirability of Outcome Ranking (DOOR) analysis
|
| 15.11 - 15.21 | OC 60 Selected comorbidities and the risk of ART switch in the context of HIV-RNA suppressed to ≤50 copies/mL
|
| 15.23 - 15.30 | Conclusion
F. Mazzotta, M.E. Quiros Roldan |
Oral Communications
Prevention, access and engagement
Oral Communications
Prevention, access and engagement
Chairs: M.L. Cosmaro, E. Girardi
| 15.35 - 15.40 | Introduction
M.L. Cosmaro, E. Girardi |
| 15.40 - 15.50 | OC 69 A nurse-led HIV/STI prevention program in a Voluntary Counselling and Testing site in the metropolitan area of Rome
|
| 15.52 - 16.02 | OC 70 Epidemiological impact of pre-exposure prophylaxis in HIV prevention: a single center observational experience in pre and post prophylaxis era
|
| 16.04 - 16.14 | OC 71 Late HIV diagnosis: the new consensus definition reduces the proportion of late presentations
|
| 16.16 - 16.26 | OC 72 Impact of COVID-19 pandemic on retention in care of native and migrant PLWH in the ICONA cohort
|
| 16.28 - 16.35 | Conclusion
M.L. Cosmaro, E. Girardi |
Oral Communications
Clinical outcome of SARS-CoV-2 infection
Oral Communications
Clinical outcome of SARS-CoV-2 infection
Chairs: R. Gagliardini, R. Gulminetti
| 16.40 - 16.45 | Introduction
R. Gagliardini, R. Gulminetti |
| 16.45 - 16.55 | OC 83 Association between vaccination status and disease severity in patients (pts) hospitalized for COVID-19: data from a national reference hospital
|
| 16.57 - 17.07 | OC 84 Anti-spike SARS-CoV-2 antibody titer and risk of clinical progression in patients with COVID19-related pneumonia
|
| 17.09 - 17.19 | OC 85 Vaccination against SARS-CoV-2 after the natural infection, is associated with a reduced risk of late-onset thrombotic and cardiovascular events (18-months analysis, on the “Surviving-COVID” Cohort, Bergamo)
|
| 17.21 - 17.31 | OC 86 Long-term assessment of anti-SARS-CoV-2 immunogenicity after a mRNA vaccine in PLWH
|
| 17.33 - 17.40 | Conclusion
R. Gagliardini, R. Gulminetti |
Special Session
Health and prevention in transgender people
Special Session
Health and prevention in transgender people
Studies carried out across a variety of different contexts have shown that transgender and gender diverse (TGD) people face significant barriers to accessing health care and health-determining resources, such as education, employment and housing. Harassment and discrimination contribute to high rates of stress and make transgender individuals significantly more likely to experience poor health outcomes (e.g., high risk for mental health morbidity, STI, cardiac disease, etc). Thus, it is urgently warranted to provide an effective and appropriate evidence-based prevention and care so as to ensure health equity for transgender people. In particular, TGD people are at high risk for HIV infection but prevention efforts targeting these people have been minimal. HIV pre-exposure prophylaxis (PrEP) is highly effective at preventing HIV, however PrEP use among TGD people remains low. In this section, an overview of the main barriers that TGD people have to face accessing healtcare services will be given and possible future strategies will be discussed.
Chair: A. Palmitesta
| 11.10 - 11.25 | In-practice policies to promote an inclusive health care for transgender People
M. Pierdominici |
| 11.25 - 11.40 | Transgender health and communication strategies: the website Infotrans.it
M. Marconi |
| 11.40 - 11.55 | Sociosanitary conditions of transgender PWHIV: photography and possible inclusion tools
L. Brogonzoli |
| 11.55 - 12.10 | Barriers in the use HIV prophylaxis in transgender individuals
T. Bini |
Parallel Session
ARCA Scientific Board
Parallel Session
ARCA Scientific Board
La riunione del Board Scientifico tratterà lo stato attuale della coorte con un update sulle attività in corso e le prospettive progettuali, incluso il prossimo meeting ARCA Mentor School in programma a settembre a Siena.
Special Session
The Italian Fast-track Cities: strengths and weaknesses of a growing movement
Special Session
The Italian Fast-track Cities: strengths and weaknesses of a growing movement
Since December 2018, when Milan, the first Italian city, joined the global network of Fast-track Cities Initiative, the number of participating cities has steadily increased. This movement is one of the most important innovation in the national overview of territorial actions to reach the UNAIDS 95-95-95 goal by 2030. However, this growth is characterized by light and shadow. Some cities are blocked in their first declaration of intent or have difficulties in developing necessary collaboration between public institutions and social organisations in order to achieve tangible actions. Others cities are totally changing the face of fight against HIV in their own territories. A further difficulty, but which is also a possibility, concerns the sharing of good practices and the most effective actions between Italian Fast-track Cities.
Chairs: P. Meli, G. Orofino
| 15.35 - 15.45 | Activities in the last year of the Italian FTCs
I. Mercurio |
| 15.45 - 15.55 | The U=U campaign of the city of Turin
S.R. Patrucco |
| 15.55 - 16.05 | The first steps of the city of Ancona
L. Saracini |
| 16.05 - 16.15 | A project for the most vulnerable people in the city of Bergamo
D. Meli |
| 16.15 - 16.35 | Common projects and actions are possible? |
08:30 - 09:00 | Special Session
ICAR-CROI Awards 2023
09:00 - 10:30
Keynote Lectures
10:35 - 11:35 | Sponsored Symposium
Cabotegravir + Rilpivirine Long-Acting: a new dawn for PLHIV
11:40 - 12:40 | Symposium
The battle between the virus and the host: an ongoing dynamic process
12:45 - 13:45 | Symposium
Clinical COVID-19
14:00 - 15:00 | Symposium
Clinical HIV first! Emerging and re-emerging clinical issues in HIV infection
15:05 - 16:05 | Symposium
Chemsex emergency - what happens in real life
16:10 - 16:30 | Special Session
ICAR 2023 Awards and Closing remarks
10:35 - 11:35 | Oral Communications
Bench studies of viral infections
11:40 - 12:40 | Oral Communications
Innovative tools for diagnosis and monitoring of viral infections
12:45 - 13:45 | Special Session
Drug pipeline: a glimpse of the future
14:00 - 15:00 | Oral Communications
Body and mind
15:05 - 16:05 | Oral Communications
Outcomes in treatment experienced PLWH
10:35 - 11:35 | Oral Communications
Liver, vessels and lipids
11:40 - 12:40 | Oral Communications
The experience of PrEP in Italy
12:45 - 13:45 | Oral Communications
Education and knowledge to reduce the burden of HIV and STIs
14:00 - 15:00 | Oral Communications
PACS: clinical outcome
15:05 - 16:05 | Oral Communications
Clinical approach to COVID in vulnerable populations
10:35 - 11:35 | Oral Communications
PACS: what to assess
11:40 - 12:40 | Oral Communications
Virological topics in SARS-CoV-2 infection
12:45 - 13:45 | Oral Communications
Real world evidence in different treatment setting
14:00 - 15:00 | Oral Communications
Viruses, resistance and drugs
15:05 - 16:05 | Oral Communications
Emerging issues in HIV-1 infection
14:00 - 15:00 | Oral Communications
Mpox and Immunopathogenic mechanisms
15:05 - 16:05 | Oral Communications
Novel clinical and epidemiological aspects of viral hepatitis
10:35 - 11:35 | Special Session
U=U: Impossibile Sbagliare
11:40 - 12:40 | Parallel Session
Meeting Prestigio Registry
12:50 - 14:00 | Parallel Session
HIV Outcomes in Europe
14:05 - 15:35 | Parallel Session
Investigator Meeting of EDOLAS study Efficacy and safety of early switching to dolutegravir/lamivudine (DTG/3TC) from INSTI-based three-drug regimens in HIV-1-infected adults previously naïve who achieve virological suppression
Special Session
ICAR-CROI Awards 2023
Special Session
ICAR-CROI Awards 2023
This session is devoted to Young Italian Researchers - under 40 - who had an abstract accepted at CROI 2023. The following prizes will be announced and awarded: Two prizes for the best Clinical and Basic science Abstracts
Chairs: G. Angarano, F. Ceccherini Silberstein, G. d'Ettorre
| Introduction | |
· Prevalence, incidence, and risk factors for falls in older people with and without HIV S. Arsuffi |
|
· High RNAemia associates with skewed T-Cell response in PLWH hospitalized for COVID-19 M. Augello |
|
· Efficacy of 3TC+DTG vs 3-drug regimens in virologically-suppressed PLWH A. Borghetti |
|
· Mpox DNA clearance in semen over six months follow-up C. Candela |
|
· Increased burden of anal HPV-related potentially precancerous lesions in HIV+ women · Efficacy of late HPV vaccination in young HIV+ MSM E.N. Cavallari |
|
· Leukapheresis: a feasible tool to inform ati through HIV rereservoir study in children N. Cotugno |
|
· The impact of early outpatient treatments for COVID-19: a retrospective study M. Degli Antoni |
|
· mRNA vaccines induces a higher antibodies response in children with previous COVID-19 C. Di Chiara |
|
· Anemia as a predictor of poor clinical outcome in patients admitted for COVID-19 · Impact of the COVID-19 pandemic on Malaria services in Uganda: a time series analysis F. Di Gennaro |
|
· A joint analysis of two randomized controlled trials on enoxaparin for COVID-19 G. Dolci |
|
· Effects of chemoradiation on expanded proviral clones in an elite controller F. Dragoni |
|
· Mpox Virus in the pharynx of men having sex with men: a case series S. Limonta |
|
· Inflammasone but not IFN-I/III response is altered in children with long COVID L. Maddaloni |
|
· Screening approaches and clinical description of the anticholinergic burden in people with HIV M. Mazzitelli |
|
· Neutralizing and T cell response against mpox virus after MVA-BN vaccine · Comparison of subcutaneous versus intradermal route of administration of MVA vaccine · Humoral and cellular immune response after 3 months from Mpox Virus infection · SARS-CoV-2 Omicron viral load decrease after monoclonal antibodies or antivirals · Incidence and predictors of clinical progression in an early treated COVID-19 Cohort V. Mazzotta |
|
· Mortality linked to higher inflammation in perinatally-infected HIV+ kids E. Marrocchi |
|
· Immunogenicity of MVA-BN vaccination with hybrid administration route D. Moschese |
|
· Multifaceted premature aging in adolescent/young adult with perinatal-acquired HIV M.R. Petrara |
|
· Delayed positivization of non-lesion specimens among individuals with Mpox A.R. Raccagni |
|
· Adaptive immunity dysregulation is associated to the development of long COVID R. Rovito |
|
· Cap and metabolic profile worsening post-SRV in HCV-HIV people as a sign of steatosis A. Siribelli |
|
· DTG impact Zebrafish behaviour through dopaminergic pathways: rescue by folate S. Storti |
|
· The cerebrospinal fluid virome in virally suppressed people living with HIV · Neurocognitive impairment negatively affects viral control in Art-Treated PWH M. Trunfio |
|
· Neutralizing activity and T cell response after bivlent third booster dose in PLWH A. Vergori |
Keynote Lectures
Keynote Lectures
Chairs: G. Angarano, R. Cauda, A. Cossarizza
| 09.00 - 09.30 | Mpox 2022: the story of another pandemics
A. Antinori |
| 09.30 - 10.30 | COVID-19: virus vs immunocompromised host
M.S. Clerici |
| 09.30 - 10.30 | COVID-19: virus vs immunocompromised host
C.F. Perno |
Sponsored Symposium
Cabotegravir + Rilpivirine Long-Acting: a new dawn for PLHIV
Simposio promozionale di:
Sponsored Symposium
Cabotegravir + Rilpivirine Long-Acting: a new dawn for PLHIV
Long-acting regimens can help people living with HIV to overcome some challenges that have not yet been completely resolved. Today, we are one year from the reimbursement of CABOTEGRAVIR + RILPIVIRINE Long-acting, the first complete long-acting regimen indicated for the treatment of HIV in virologically suppressed patients. The goal of the symposium is to share new scientific evidence supporting the efficacy and safety of CAB+RPV LA, both from clinical trials and local experiences.
Chair: G. Nunnari
Discussants: N. Gianotti, C. Mussini, R. Rossotti, A. Saracino
| 10.35 - 10.40 | Introduction
G. Nunnari |
| 10.40 - 11.00 | SOLAR study: the dawn of a new era
G. Di Perri |
| 11.00 - 11.30 | Roundtable: the experience starts with you |
| 11.30 - 11.35 | Take home message
G. Nunnari |
Symposium
The battle between the virus and the host: an ongoing dynamic process
Symposium
The battle between the virus and the host: an ongoing dynamic process
The symposium is intended to address different topics concerning the delicate balance between protective and pathogenetic role of the immune system over viral infections. In particular, a comprehensive review of the most recent notions on early events (Type-I IFN-s) after HIV and SARS-CoV-2 infection will be provided. The role exerted by host immune factors and ART to contain HIV reservoir will be illustrated as well. The most novel technical approaches to gain exhaustive and more and more detailed information from biological specimens of infected patients will also be thoroughly reviewed during the symposium.
Chairs: C. Agrati, A. Cossarizza
| 11.40 - 11.55 | Type I Interferon in HIV and SARS-CoV-2 infection: following the mechanistic thread
C. Scagnolari |
| 11.55 - 12.10 | Drivers for virus reservoir containment: ART or host immune responses
A. De Maria |
| 12.10 - 12.25 | From bed to bench and return: what happens in between?
S. De Biasi |
| 12.25 - 12.40 | Discussion |
Symposium
Clinical COVID-19
Symposium
Clinical COVID-19
The symposium will present virological and clinical paradigms in the prophylaxis and treatment of SARS COV2 infection. In a multidisciplinary approach we will invite a psychiatrist to discuss immune-inflammatory pathways leading to psychopathology and neurocognitive impairment in LongCOVID with a focus on target for treatment. It will end with a round table comparing different models of care in the management of people with LongCOVID highlighting unmet clinical needs and research opportunities.
Chairs: G. Guaraldi, L. Sarmati
Moderator: G.C. Marchetti
Discussants: M. Andreoni, F. Benedetti, A.M. Cattelan, G. Guaraldi, G. Onder
| 12.45 - 13.00 | Paradigms of a prophylax and early treatment in COVID-19
M. Andreoni |
| 13.00 - 13.15 | Psychopathology and neurocognitive impairment in Long COVID: Immunopsychiatry of Long COVID
F. Benedetti |
| 13.15 - 13.45 | Round table |
| 13.15 - 13.25 | Introduction Lecture Challenges in Long-COVID care: Italian experiences and best practices
G. Onder |
| 13.25 - 13.45 | Discussion |
Symposium
Clinical HIV first! Emerging and re-emerging clinical issues in HIV infection
Symposium
Clinical HIV first! Emerging and re-emerging clinical issues in HIV infection
HIV infection has taken on clinical connotations in the last two decades that are certainly different from what was observed at the beginning of the HIV epidemic. These changes have been induced by the universal use of antiretroviral therapy in our latitudes, although where therapy is not universally available, some clinical pictures may appear different and more similar to what was previously observed. The aim of this symposium is, on the one hand, to bring back the attention especially of young physicians to the classical clinical aspects of HIV infection by focusing on syndromic aspects in different situations of universal availability of ART, especially in terms of late presentation; on the other hand, it is intended to focus attention on particular clinical situations, toward which the availability of new treatments could change the natural history and prognosis of the diseases themselves, such as progressive multifocal leukoencephalopathy and HIV-related neoplasms.
Chairs: A. Bandera, G. Nunnari
| 14.00 - 14.20 | Syndromic approach to main opportunistic infections in HIV. Focus on limited resources - vs rich resources countries
C. Pinnetti |
| 14.20 - 14.40 | Progressive multifocal leucoencephalopathy. Update on diagnostics and therapeutic approaches
P.M. Cinque |
| 14.40 - 15.00 | New insights into innovative anti-cancer therapies and their application in HIV-related cancers
E. Vaccher |
Symposium
Chemsex emergency - what happens in real life
Symposium
Chemsex emergency - what happens in real life
Chemsex, or the use of recreational substances during sex, is a widespread practice within the MSM community. Numerous cohort studies on HIV-positive MSM or PrEP users show that the prevalence of the phenomenon is increasing and the substances used are constantly evolving. The chemsex emergency is often spoken of with emphasis on the health and addiction issues related to drug use, but also with a good deal of ignorance leading to stigmatisation of users. The symposium aims to shed light on this practice, providing information on the type of substances most commonly used, the contribution of peer practitioners in the field who, within community associations, offer support to chemsex users, and finally the fundamental role of PrEP in reducing the risk of HIV infection in contexts where other prevention tools would be of doubtful effectiveness.
Chairs: M.G.L. Cernuschi, D. Zagato
| 15.05 - 15.20 | Old and new psychotropic substances in chemsex practice
M. Lanza |
| 15.20 - 15.40 | Recreational Chemsex Vs problematic Chemsex
F. Leserri |
| 15.20 - 15.40 | Recreational Chemsex Vs problematic Chemsex
M. Manfredini |
| 15.40 - 15.50 | Chemsex & PrEP
S. Nozza |
| 15.50 - 16.05 | Discussion |
Special Session
ICAR 2023 Awards and Closing remarks
Special Session
ICAR 2023 Awards and Closing remarks
ICAR and SIMIT support and reward the young excellences of Italian research with special prizes announced and awarded during this Session.
Chairs: F. Ceccherini Silberstein, M. Formisano, S. Lo Caputo, F. Maggiolo, C.M. Mastroianni, A. Saracino
| ICAR 2023 Awards and Closing remarks |
Oral Communications
Bench studies of viral infections
Oral Communications
Bench studies of viral infections
Chairs: S. Parisi, C. Scagnolari
| 10.35 - 10.40 | Introduction
S. Parisi, C. Scagnolari |
| 10.40 - 10.50 | OC 87 Prevalence and phenotypic susceptibility to doravirine of the HIV-1 reverse transcriptase V106I polymorphism in B and non-B subtypes
|
| 10.52 - 11.02 | OC 88 The in vitro effects of dolutegravir and bictegravir on musculoskeletal cells
|
| 11.04 - 11.14 | OC 89 Pharmacokinetics of First-line Antitubercular Drugs in People Living with HIV and Controls in a Therapeutic Drug Monitoring Registry
|
| 11.16 - 11.26 | OC 90 Extracellular vesicles designed to decoy or compete with spike binding to the human ACE2 receptor of SARS-CoV-2 highlight the diversity of Omicron spike
|
| 11.28 - 11.35 | Conclusion
S. Parisi, C. Scagnolari |
Oral Communications
Innovative tools for diagnosis and monitoring of viral infections
Oral Communications
Innovative tools for diagnosis and monitoring of viral infections
Chairs: C. Alteri, C. Torti
| 11.40 - 11.45 | Introduction
C. Alteri, C. Torti |
| 11.45 - 11.55 | OC 99 Preliminary evaluation on the relevance of CSF cell-free mitochondrial DNA in different setting of viral neuroinflammatory diseases
|
| 11.57 - 12.07 | OC 100 Serum Antibody Fingerprinting for SARS-CoV-2 Variants by Label-Free Microarray Biosensor
|
| 12.09 - 12.19 | OC 101 Molecular diagnosis of human Monkeypox virus in the 2022 outbreak: preliminary evaluation of novel real-time qualitative PCR assays
|
| 12.21 - 12.31 | OC 102 Kinetic of TTV DNA load in peripheral blood lymphomonocytes in early treated acute HIV infections
|
| 12.33 - 12.40 | Conclusion
C. Alteri, C. Torti |
Special Session
Drug pipeline: a glimpse of the future
Special Session
Drug pipeline: a glimpse of the future
An open discussion between researchers and R&D representatives of pharmaceutical companies that aims to outline and shape the future of antiviral drug and vaccines development in the next decade
Chairs: C. Mussini, C.F. Perno, S. Vella
| 12.45 - 12.50 | Introduction |
| 12.50 - 12.55 | Emiliano Bissio, Global Director Medical Affairs (HIV) at MSD |
| 12.55 - 13.00 | Gian Marco Prandi, Director Medical Affairs Vaccines at MSD Italy |
| 13.00 - 13.10 | Martin Gartland, Vice President, Early Development Lead, Pipeline at ViiV Healthcare |
| 13.10 - 13.20 | Felipe Rogatto, Executive Director of Global HIV Medical Affairs - Franchise & Strategic Implementation at Gilead Sciences |
| 13.20 - 13.25 | Foteini Gkalapi, Medical Lead Vaccines Europe - Belgium at GSK |
| 13.25 - 13.30 | Shayon Salehi, Medical Director, Global Medical Affairs at GSK |
| 13.30 - 13.45 | Q&A and Discussion |
Oral Communications
Body and mind
Oral Communications
Body and mind
Chairs: T. Bini, G. Rizzardini
| 14.00 - 14.05 | Introduction
T. Bini, G. Rizzardini |
| 14.05 - 14.15 | OC 119 BMI vs body composition changes to predict metabolic outcomes in people with HIV
|
| 14.17 - 14.27 | OC 120 Prevalence, incidence and risk factors for sarcopenic obesity in people with HIV
|
| 14.29 - 14.39 | OC 121 Plasma and CSF biomarkers of CNS involvement during primary HIV infection
|
| 14.41 - 14.51 | OC 122 The effects of switching from dolutegravir/abacavir/lamivudine to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people living with HIV on neuropsychiatric symptoms: 3-months findings from a randomized study
|
| 14.53 - 15.00 | Conclusion
T. Bini, G. Rizzardini |
Oral Communications
Outcomes in treatment experienced PLWH
Oral Communications
Outcomes in treatment experienced PLWH
Chairs: A.M. Cattelan, A. Moznich
| 15.05 - 15.10 | Introduction
A.M. Cattelan, A. Moznich |
| 15.10 - 15.20 | OC 135 Effectiveness of switch to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in virologically suppressed persons living with HIV (PLWH): 96-week data from the Icona cohort
|
| 15.22 - 15.32 | OC 136 Effectivness of bictegravir/emtricitabine/tenofovir alafenamide(BIC/FTC/TAF) as switch strategy in virologically suppressed: real world data from monocentric cohort
|
| 15.34 - 15.44 | OC 137 Use of tenofovir alafenamide/emtricitabine/bictegravir (B/F/TAF) in treatment-experienced people living with HIV. Real-life data from Infectious Disease Unit of Alessandro Manzoni Hospital in Lecco
|
| 15.46 - 15.56 | OC 138 Safety and efficacy of doravirine-based regimens in People Living With HIV: a real-life multicentric study
|
| 15.58 - 16.05 | Conclusion
A.M. Cattelan, A. Moznich |
Oral Communications
Liver, vessels and lipids
Oral Communications
Liver, vessels and lipids
Chairs: P. Blanc, A. Cingolani
| 10.35 - 10.40 | Introduction
P. Blanc, A. Cingolani |
| 10.40 - 10.50 | OC 91 To TAF or not to TAF? What is the difference? Data from a real-life setting
|
| 10.52 - 11.02 | OC 92 LDL-c target achievement in people living with HIV according to individual cardiovascular risk: a retrospective single center observational study
|
| 11.04 - 11.14 | OC 93 Evaluation of intimal thickness and atheromatous plaques in HIV-experienced vs HIV-negative patients: data from the Archiprevaleat cohort
|
| 11.16 - 11.26 | OC 94 Risk factors for liver fibrosis progression in HIV: a multi-center longitudinal study
|
| 11.28 - 11.35 | Conclusion
P. Blanc, A. Cingolani |
Oral Communications
The experience of PrEP in Italy
Oral Communications
The experience of PrEP in Italy
Chairs: E. Focà, F.P. Maraglino
| 11.40 - 11.45 | Introduction
E. Focà, F.P. Maraglino |
| 11.45 - 11.55 | OC 103 PrEP in Italy: increased coverage despite significant barriers to access
|
| 11.57 - 12.07 | OC 104 Daily or On Demand Oral HIV Pre-exposure Prophylaxis: a Comparison of Users’ Characteristics and Sexually Transmitted Infection Features
|
| 12.09 - 12.19 | OC 105 Confidence in the “Undetectable Equals Untransmittable” (U=U) paradigm among PrEP users
|
| 12.21 - 12.31 | OC 106 MDPV awareness and preparedness among PrEP users: a community survey
|
| 12.33 - 12.40 | Conclusion
E. Focà, F.P. Maraglino |
Oral Communications
Education and knowledge to reduce the burden of HIV and STIs
Oral Communications
Education and knowledge to reduce the burden of HIV and STIs
Chairs: N. Frattini, R. Galipò
| 12.45 - 12.50 | Introduction
N. Frattini, R. Galipò |
| 12.50 - 13.00 | OC 111 Community based voluntary counselling and testing (CBVCT) services for HIV and other sexual transmissed diseases offered during the pandemic
|
| 13.02 - 13.12 | OC 112 Knowledge, Attitudes and Practices regarding HIV and other Sexually Transmitted Infections among High School Students in Southern Italy: a cross-sectional survey
|
| 13.14 - 13.24 | OC 113 Knowledge reduces stigma and generates awareness. The experience of the #cHIVuoleconoscere project in Bergamo
|
| 13.26 - 13.36 | OC 114 Just LILA - A pilot project and promotional campaign to promote self-testing
|
| 13.38 - 13.45 | Conclusion
N. Frattini, R. Galipò |
Oral Communications
PACS: clinical outcome
Oral Communications
PACS: clinical outcome
Chairs: G. Cenderello, D. Ripamonti
| 14.00 - 14.05 | Introduction
G. Cenderello, D. Ripamonti |
| 14.05 - 14.15 | OC 123 Long COVID phenotypes and association with SARS CoV-2 variants in the EUCARE-POSTCOVID study
|
| 14.17 - 14.27 | OC 124 Implication of Human Endogenous Retroviruses in development, progression and long-term sequelae of COVID-19: towards a personalized medicine
|
| 14.29 - 14.39 | OC 125 Impact of long-COVID on daily working activity in non-elderly patients: a cross sectional study
|
| 14.41 - 14.51 | OC 126 Symptom clusters and risk factors for Long COVID syndrome in hospitalized patients at 6 months of follow up
|
| 14.53 - 15.00 | Conclusion
G. Cenderello, D. Ripamonti |
Oral Communications
Clinical approach to COVID in vulnerable populations
Oral Communications
Clinical approach to COVID in vulnerable populations
Chairs: F. Di Gennaro, C. Gervasoni
| 15.05 - 15.10 | Introduction
F. Di Gennaro, C. Gervasoni |
| 15.10 - 15.20 | OC 139 Efficacy and safety of therapies for COVID-19 in pregnancy: a systematic review and meta-analysis
|
| 15.22 - 15.32 | OC 140 SARS-CoV2 infection in patients with Hematological Malignancies in the omicron era: hospitalization, need for mechanical ventilation and mortality in seronegative and seropositive population
|
| 15.34 - 15.44 | OC 141 Antibody response in women vaccinated against SARS-CoV-2 during pregnancy and respective babies at birth and after a nine-months follow-up
|
| 15.46 - 15.56 | OC 142 Safety of Antiviral therapy in fragile SARS COV 2 paediatric patients
|
| 15.58 - 16.05 | Conclusion
F. Di Gennaro, C. Gervasoni |
Oral Communications
PACS: what to assess
Oral Communications
PACS: what to assess
Chairs: G. Guaraldi, L. Sarmati
| 10.35 - 10.40 | Introduction
G. Guaraldi, L. Sarmati |
| 10.40 - 10.50 | OC 95 Assessing health status dynamics in people with post-acute COVID-19 syndrome comparing patient reported outcome measures with physical functioning, sarcopenia and frailty
|
| 10.52 - 11.02 | OC 96 Frailty transitions in people with Post-Acute COVID Syndrome
|
| 11.04 - 11.14 | OC 97 12-month follow-up of the long COVID during three pandemic years
|
| 11.16 - 11.26 | OC 98 A picture of psychological symptoms and coping strategies within post COVID-19 population
|
| 11.28 - 11.35 | Conclusion
G. Guaraldi, L. Sarmati |
Oral Communications
Virological topics in SARS-CoV-2 infection
Oral Communications
Virological topics in SARS-CoV-2 infection
Chairs: S. Carbonara, I. Vicenti
| 11.40 - 11.45 | Introduction
S. Carbonara, I. Vicenti |
| 11.45 - 11.55 | OC 107 A heparan sulfate proteoglycan binding tetrapeptide successfully inhibits SARS-CoV-2 Omicron replication
|
| 11.57 - 12.07 | OC 108 Synergistic effects of antivirals and monoclonal antibodies in vitro against SARS-CoV-2 Wild Type B.1 strain and BQ.1.1 Omicron sublineage
|
| 12.09 - 12.19 | OC 109 In vitro modelling to monitor pathogenic implications of RSV and SARS-CoV-2 co-infection
|
| 12.21 - 12.31 | OC 110 Efficacy and SARS CoV-2 viral decay in nasopharynx, saliva and plasma in high-risk vaccinated patients treated with monoclonal antibodies (mAb)
|
| 12.33 - 12.40 | Conclusion
S. Carbonara, I. Vicenti |
Oral Communications
Real world evidence in different treatment setting
Oral Communications
Real world evidence in different treatment setting
Chairs: A. Di Biagio, M. Poliseno
| 12.45 - 12.50 | Introduction
A. Di Biagio, M. Poliseno |
| 12.50 - 13.00 | OC 115 Adherence to and forgiveness to imperfect adherence of FTC/TAF/RPV
|
| 13.02 - 13.12 | OC 116 Adherence to and forgiveness to imperfect adherence of B/F/TAF
|
| 13.14 - 13.24 | OC 117 Antiretroviral therapy prescription in older people living with HIV: cross-sectional study on multidrug regimens (MDR) and less drug regimens (LDR) in GEPPO cohort
|
| 13.26 - 13.36 | OC 118 Reasons for choosing a doravirine (DOR) based versus an INSTI-based regimen in ART-naïve and ART-experienced patients in real-world setting: data from the Icona Cohort
|
| 13.38 - 13.45 | Conclusion
A. Di Biagio, M. Poliseno |
Oral Communications
Viruses, resistance and drugs
Oral Communications
Viruses, resistance and drugs
Chairs: B. Bruzzone, F. Saladini
| 14.00 - 14.05 | Introduction
B. Bruzzone, F. Saladini |
| 14.05 - 14.15 | OC 127 Does NGS on HIV-1 DNA improve resistance assessment in highly treatment-experienced and multi-resistant individuals under virological control? An experience from the PRESTIGIO Registry
|
| 14.17 - 14.27 | OC 128 HIV-1 persistence in people living with HIV who started antiretroviral therapy in acute or chronic infection: insight into molecular mechanisms
|
| 14.29 - 14.39 | OC 129 Comparison of different interpretation tools for HIV-1 resistance detected through Next Generation Sequencing in Italian clinical routine
|
| 14.41 - 14.51 | OC 130 Pharmacokinetic of tecovirimat in plasma and semen of Mpox patients
|
| 14.53 - 15.00 | Conclusion
B. Bruzzone, F. Saladini |
Oral Communications
Emerging issues in HIV-1 infection
Oral Communications
Emerging issues in HIV-1 infection
Chairs: B.M. Celesia, G. Giupponi
| 15.05 - 15.10 | Introduction
B.M. Celesia, G. Giupponi |
| 15.10 - 15.20 | OC 143 Impact of COVID-19 in time to linkage to care (LtC) and ART initiation in the ICONA cohort
|
| 15.22 - 15.32 | OC 144 Risk of COVID-19 in-hospital mortality in people living with HIV compared to general population according to age and CD4 strata: data from the Icona network
|
| 15.34 - 15.44 | OC 145 Patient reported outcomes in older people living with/without HIV in the GEPPO cohort
|
| 15.46 - 15.56 | OC 146 Implementing an Electronic Patient-Reported Outcomes (ePROs) system in PLWH management: experience of Icona cohort
|
| 15.58 - 16.05 | Conclusion
B.M. Celesia, G. Giupponi |
Oral Communications
Mpox and Immunopathogenic mechanisms
Oral Communications
Mpox and Immunopathogenic mechanisms
Chairs: F. Maggi, V. Mazzotta
| 14.00 - 14.05 | Introduction
F. Maggi, V. Mazzotta |
| 14.05 - 14.15 | OC 131 Humoral and cellular immune response after eight months from Mpox virus infection
|
| 14.17 - 14.27 | OC 132 Neutralizing and T cell immunogenicity after MVA-BN vaccination for mpox according to previous smallpox vaccination, HIV status, and administration route
|
| 14.29 - 14.39 | OC 133 Interferon-gamma (IFN-g), But Not Tumor Necrosis Factor-alpha (TNF-a) Induces the Polarization of Human Monocyte-Derived Macrophage (MDM) into M1 Cells Restricting HIV-1 Replication
|
| 14.41 - 14.51 | OC 134 Effect of sera from HIV-1-exposed seronegative subjects, long term non progressors, HIV-1+ and HIV-1- individuals on CCR5 expression and R5 HIV-1 infectivity in human primary macrophages and CD4+ T lymphocytes
|
| 14.53 - 15.00 | Conclusion
F. Maggi, V. Mazzotta |
Oral Communications
Novel clinical and epidemiological aspects of viral hepatitis
Oral Communications
Novel clinical and epidemiological aspects of viral hepatitis
Chairs: G. Lapadula, T.A. Santantonio
| 15.05 - 15.10 | Introduction
G. Lapadula, T.A. Santantonio |
| 15.10 - 15.20 | OC 147 HDV replicative activity parallels the production of the three HBsAg forms (Large, Middle and Small HBsAg) and its pathogenetic impact is exacerbated by concomitant HBV replication
|
| 15.22 - 15.32 | OC 148 Management of antiviral prophylaxis in patients with resolved HBV infection receiving immunosuppressive treatment
|
| 15.34 - 15.44 | OC 149 HDV infection is stable in Central Italy across the last two decades and is characterized by the circulation of multiple HDV sub-genotypes 1 with a different pro-inflammatory potential
|
| 15.46 - 15.56 | OC 150 Prevalence and outcome of Hepatitis Delta virus (HDV) infection among Persons Living with HIV (PLWH) in Italy: the Delta-Icona study
|
| 15.58 - 16.05 | Conclusion
G. Lapadula, T.A. Santantonio |
Special Session
U=U: Impossibile Sbagliare
Special Session
U=U: Impossibile Sbagliare
U=U represents the most revolutionary principle and the most effective tool to break down stigma and discrimination against people living with HIV (PLWH) and to improve acceptance of infection and break down self-stigma in PLWH themselves. For this, ICAR's Community Associations constructed a "prospective study to evaluate the impact of a U=U information campaign in two target populations": PLWH and the general population. In this first phase, the construction of the study will be explained and the communication campaign "U=U: No brainer" will be presented.
Chairs: M. Farinella, F. Schloesser
| 10.35 - 11.35 | Presentation of the communication campaign and methodologies of the impact assessment study
D. Calzavara, N. Frattini |
Parallel Session
Meeting Prestigio Registry
Parallel Session
Meeting Prestigio Registry
The PRESTIGIO REGISTRY opens its doors to the ICAR community. The meeting will be an opportunity to share the updated profile of the Registry, as well as to present the achievements, ongoing initiatives and research projects to all participating centers.
Chair: A. Castagna
| 11.40 - 11.55 | PRESTIGIO Registry Update
A. Castagna |
| 11.55 - 12.10 | Publications
L. Galli |
| 12.10 - 12.25 | Current initiatives and research projects
V. Spagnuolo |
| 12.25 - 12.40 | Questions and Answers
E. Carini |
| 12.25 - 12.40 | Questions and Answers
R. Lolatto |
Parallel Session
HIV Outcomes in Europe
Parallel Session
HIV Outcomes in Europe
HIV Outcomes is a European initiative born in 2016, thanks to the support of the members of the European Parliament, bringing together patient organisations, clinicians, academics, public institutions and the private sector to think about a new way of addressing the needs of HIV-positive people, to guarantee that they can live longer, in good health and fully participate in society. HIV Outcomes aims to sensitise policy makers and to implement actions that lead to a patient-centric health system that also includes a change in the clinical approach. Improving the quality of life of people living with HIV means improving the sustainability of European health systems through the sharing of best practices and innovative approaches to care. In 2017 HIV Outcomes presented its 5 Recommendations on the health, well-being and long-term care of people living with HIV to the European Parliament. In 2020, to bring the right attention on HIV of Italian political decision-makers, being at the same time members of the European Parliament, and by healthcare professionals, HIV Outcomes Italia was then created. The ultimate aim is to disseminate the recommendations and vision of HIV Outcomes Europe at national level. In 2022, the Policy Asks, developed together with national initiatives Enhancing long-term health and well-being among people living with HIV were presented to the European Parliament.
| 12.50 - 13.00 | Presentation of the initiative
A. d'Arminio Monforte |
| 13.00 - 13.10 | Policy Asks
M. Cascio |
| 13.10 - 13.15 | The involvement of the Institutions
S. Milano |
| 13.15 - 13.20 | The work done, Delphi on Recommendations and initial Institutions engagement
A. d'Arminio Monforte |
| 13.20 - 13.25 | Abstract on Surveys on Residential care Homes and Hospitals
L. Brogonzoli |
| 13.25 - 13.40 | The way forward on Ageing
M. Cascio, A. d'Arminio Monforte |
| 13.40 - 14.00 | Questions and Answers |
Parallel Session
Investigator Meeting of EDOLAS study Efficacy and safety of early switching to dolutegravir/lamivudine (DTG/3TC) from INSTI-based three-drug regimens in HIV-1-infected adults previously naïve who achieve virological suppression
Parallel Session
Investigator Meeting of EDOLAS study Efficacy and safety of early switching to dolutegravir/lamivudine (DTG/3TC) from INSTI-based three-drug regimens in HIV-1-infected adults previously naïve who achieve virological suppression
| 14.05 - 14.10 | Welcome
A. Antinori, F. Maggiolo |
| 14.10 - 14.15 | Introduction
A. Antinori, F. Maggiolo |
| 14.15 - 14.30 | Protocol and enrolments
R. Gagliardini |
| 14.30 - 14.50 | Discussion |
| 14.50 - 15.30 | Meeting with investigators of the Edolas substudies |
| 15.30 - 15.35 | Conclusions
A. Antinori |
Promosso da
